Zelboraf (Vemurafenib) Patent Expiration, LOE Window & CMS Spending
Zelboraf (Vemurafenib) by Roche / Genentech: FDA Orange Book core substance LOE 2030-07-27 (last listed 2032-06-06), 0 AB generics, $15.8M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Roche / Genentech |
| FDA Application & Pathway | N202429 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2030-07-27 |
| Last Listed Patent or Exclusivity Date | 2032-06-06 |
| Orange Book Patents (*PED Extensions) | 6 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $15.8M |
| 2024 Medicare Part D Spend | $13.4M |
| 2024 Medicaid Spend | $2.4M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.